31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
Casey R. Ager(Columbia University Irving Medical Center), Yvonne M. Saenger(Penn Presbyterian Medical Center), Ashvin R. Jaiswal(The University of Texas MD Anderson Cancer Center), Fabien Chanuc(Innate Pharma (France)), Hormas Ghadially, Peter Berglund, Todd Bartkowiak(Vanderbilt University), Bernie Fitzharris(Christchurch Hospital), Robyn D. Gartrell(Johns Hopkins University), Jan ter Meulen(United States Military Academy), Yingzhi Qian(Wuhan University), John A. Thompson(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Yichun Fu(Columbia University Irving Medical Center), Jonathan Cebon(La Trobe University), Courtney Nicholas(The University of Texas MD Anderson Cancer Center), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert W. Wilkinson(Immunocore (United Kingdom)), Nicolai Wagtmann(Howard Hughes Medical Institute), Toni K. Choueiri(Harvard University), Michael B. Atkins(Georgetown University), Marianne van Vugt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Catriona M. McNeil(Chris O’Brien Lifehouse), Andrew Hill(University of Auckland), Yannis Morel(Innate Pharma (France)), Michael A. Curran(The University of Texas MD Anderson Cancer Center), Jacob Archer(Infectious Disease Research Institute), Zoë Blake(Columbia University Irving Medical Center), Georgina V. Long(The University of Sydney), Takuro Saito(Osaka International Cancer Institute), Thomas Arnoux(Innate Pharma (France)), Inês Simões(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Caroline Denis(Innate Pharma (France)), Mariëlle van Zutphen(Quantitative BioSciences), Victoria Atkinson(The University of Queensland), Matthew J. Reilley(University of Virginia Health System), Eric Mangin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Matteo S. Carlino(The University of Sydney), Tina C. Albershardt, Antoni Ribas(University of California, Los Angeles), F. Stephen Hodi(Harvard University), Rebecca S. Reeves, Nicolas Fuséri(Innate Pharma (France)), Malidi Ahamadi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yan Lu(Chinese Center For Disease Control and Prevention), Wen‐Jen Hwu(The University of Texas MD Anderson Cancer Center), Anshika Bajaj, Lisa Y. Ngo, Michael B. Jameson(Waikato Hospital), Pascale André(Innate Pharma (France)), David F. McDermott(Beth Israel Deaconess Medical Center)
Cited by 17
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k